CA3226590A1 - Bifunctional compounds for degrading btk with enhanced imid activity - Google Patents
Bifunctional compounds for degrading btk with enhanced imid activity Download PDFInfo
- Publication number
- CA3226590A1 CA3226590A1 CA3226590A CA3226590A CA3226590A1 CA 3226590 A1 CA3226590 A1 CA 3226590A1 CA 3226590 A CA3226590 A CA 3226590A CA 3226590 A CA3226590 A CA 3226590A CA 3226590 A1 CA3226590 A1 CA 3226590A1
- Authority
- CA
- Canada
- Prior art keywords
- alkyl
- membered
- heterocycloalkyl
- compound
- independently selected
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163225401P | 2021-07-23 | 2021-07-23 | |
| US63/225,401 | 2021-07-23 | ||
| PCT/US2022/038084 WO2023004163A1 (en) | 2021-07-23 | 2022-07-22 | Bifunctional compounds for degrading btk with enhanced imid activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3226590A1 true CA3226590A1 (en) | 2023-01-26 |
Family
ID=82898772
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3226590A Pending CA3226590A1 (en) | 2021-07-23 | 2022-07-22 | Bifunctional compounds for degrading btk with enhanced imid activity |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250017922A1 (https=) |
| EP (1) | EP4373493A1 (https=) |
| JP (1) | JP2024526984A (https=) |
| KR (1) | KR20240039001A (https=) |
| CN (1) | CN118019539A (https=) |
| AU (1) | AU2022313210A1 (https=) |
| CA (1) | CA3226590A1 (https=) |
| IL (1) | IL310269A (https=) |
| MX (1) | MX2024000947A (https=) |
| WO (1) | WO2023004163A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2021004191A (es) | 2018-10-15 | 2021-05-27 | Nurix Therapeutics Inc | Compuestos bifuncionales para degradar la tirosina cinasa de bruton (btk) mediante la trayectoria de ubiquitina proteosoma. |
| US12582722B2 (en) | 2019-02-13 | 2026-03-24 | Nurix Therapeutics, Inc. | Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway |
| WO2021113557A1 (en) | 2019-12-04 | 2021-06-10 | Nurix Therapeutics, Inc. | Bifunctional compounds for degrading btk via ubiquitin proteosome pathway |
| JP2024524480A (ja) * | 2021-07-01 | 2024-07-05 | ハンチョウ、ヘルズン、セラピューティクス、カンパニー、リミテッド | ブルトン型チロシンキナーゼ及びその突然変異体の分解剤、組成物並びにそれらの応用 |
| CA3236073A1 (en) | 2021-10-26 | 2023-05-04 | Robert J. Brown | Piperidinylpyrazine-carboxamide compounds for treating and preventing cancer and for degrading btk |
| CN120202200A (zh) * | 2023-06-01 | 2025-06-24 | 标新生物医药科技(上海)有限公司 | 基于氧代异吲哚啉基取代的四氢嘧啶二酮的化合物及其应用 |
| WO2025162210A1 (zh) * | 2024-02-04 | 2025-08-07 | 上海超阳药业有限公司 | 一种具备降解酪氨酸蛋白激酶btk活性的化合物及其制备方法和用途 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2021004191A (es) | 2018-10-15 | 2021-05-27 | Nurix Therapeutics Inc | Compuestos bifuncionales para degradar la tirosina cinasa de bruton (btk) mediante la trayectoria de ubiquitina proteosoma. |
| WO2021113557A1 (en) | 2019-12-04 | 2021-06-10 | Nurix Therapeutics, Inc. | Bifunctional compounds for degrading btk via ubiquitin proteosome pathway |
-
2022
- 2022-07-22 CN CN202280064042.4A patent/CN118019539A/zh active Pending
- 2022-07-22 WO PCT/US2022/038084 patent/WO2023004163A1/en not_active Ceased
- 2022-07-22 KR KR1020247006052A patent/KR20240039001A/ko active Pending
- 2022-07-22 CA CA3226590A patent/CA3226590A1/en active Pending
- 2022-07-22 IL IL310269A patent/IL310269A/en unknown
- 2022-07-22 AU AU2022313210A patent/AU2022313210A1/en active Pending
- 2022-07-22 MX MX2024000947A patent/MX2024000947A/es unknown
- 2022-07-22 US US18/290,920 patent/US20250017922A1/en active Pending
- 2022-07-22 JP JP2024504199A patent/JP2024526984A/ja active Pending
- 2022-07-22 EP EP22754662.9A patent/EP4373493A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023004163A1 (en) | 2023-01-26 |
| KR20240039001A (ko) | 2024-03-26 |
| IL310269A (en) | 2024-03-01 |
| US20250017922A1 (en) | 2025-01-16 |
| JP2024526984A (ja) | 2024-07-19 |
| EP4373493A1 (en) | 2024-05-29 |
| MX2024000947A (es) | 2024-04-12 |
| CN118019539A (zh) | 2024-05-10 |
| AU2022313210A1 (en) | 2024-02-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12600732B2 (en) | Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway | |
| CA3226590A1 (en) | Bifunctional compounds for degrading btk with enhanced imid activity | |
| US11866442B2 (en) | Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway | |
| US12582722B2 (en) | Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway | |
| US20240336595A1 (en) | Bifunctional compounds for degrading btk with diminished imid activity | |
| CA3217892A1 (en) | Compounds for inhibiting or degrading target proteins, compositions, comprising the same, methods of their making, and methods of their use | |
| US8304423B2 (en) | Modulators of muscarinic receptors | |
| US20250002489A1 (en) | Bifunctional compounds for degrading itk via ubiquitin proteosome pathway | |
| BR122023025072A2 (pt) | Usos de compostos bifuncionais para degradar btk por meio da via da ubiquitina-proteossoma | |
| US20100063021A9 (en) | Modulators of muscarinic receptors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD Year of fee payment: 2 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250610 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250610 |